London-Based Cytospire Therapeutics Raises £61M In Series A Funding

The round was led by 4BIO Capital, with participation from new investors including Servier Ventures, British Business Bank, Sound Bioventures, and Criteria Bio Ventures, alongside existing investors Abingworth and LifeArc Ventures. Additional new investors include Modi Ventures, Medical Incubator Japan, and Pathway Bioventures.

The company plans to use the funds to advance its pipeline of first-in-class pan-gamma delta T cell engagers, including its lead programme CYT X300, which is currently progressing through IND-enabling preclinical studies and GMP manufacturing.

Led by CEO Natalie Mount, Cytospire is developing multispecific antibody therapies designed to enhance immune cell activity. Its technology targets both tissue/tumour and blood-resident gamma delta T cells aiming to enable safer and more effective cancer treatments.

Read Also - Netradyne Acquires Moove Connected Mobility To Expand AI Fleet Intelligence In Europe

As part of the financing, the company has also strengthened its board with new appointments including Alexis Vandier, Carmine Circelli, and Anna Gran.

“We are excited to write the next chapter of Cytospire’s story with this fantastic group of specialist investors,” said Natalie Mount, Chief Executive Officer of Cytospire Therapeutics. “Immune cell engagers are an important type of cancer immunotherapy, but we know that there are significant limitations from both an efficacy and safety perspective with conventional CD3 T cell engagers. We are building on the growing body of translational and clinical data showing gamma delta T cells are critical components of the anti-cancer immune response, with biology ideally suited to novel cell engagers. The significant fundraise that we are announcing today reflects the quality of our team and our science, and the huge potential of our pan-gamma delta T cell engagers”.

Cytospire Therapeutics’s pan-gamma delta T cell engagers are engineered to target all gamma delta T cells rather than specific subtypes.

This approach is designed to overcome patient heterogeneity and generate broader, more effective anti-tumour immune responses by activating both tissue/tumour-resident and blood-resident effector cells.

In connection with the financing, Cytospire has also strengthened its Board of Directors with the appointments of Alexis Vandier, Carmine Circelli, and Anna Gran.

About Cytospire Therapeutics

Cytospire Therapeutics is a biotechnology company developing a portfolio of next-generation immune cell engager therapies. The company focuses on innovative multispecific antibody approaches designed to enhance the body’s immune response, aiming to create more effective and targeted treatments for cancer and other serious diseases.